Morgan Conn

Morgan Conn currently serves as Chief Financial Officer at Century Therapeutics, Inc. since October 2024, and has been a Principal at CallisBio since August 2017. Previously held the role of Chief Business Officer at Pharvaris from November 2017 to October 2024, where the focus was on developing oral alternatives to enhance care for individuals with Hereditary Angioedema (HAE). Morgan's experience also includes positions as Head of Business Development at Khondrion and various roles at PTC Therapeutics, Inc. spanning from 2001 to 2017, culminating in Vice President of Business Development. Earlier in the career, Morgan was an Assistant Professor at Amherst College, specializing in Organic Chemistry education and research. Academic credentials include a PhD in Organic Chemistry from the Massachusetts Institute of Technology, a postdoctoral fellowship in Chemical Biology from the University of California, Berkeley, and a BSc in Chemistry and Biochemistry from the University of Toronto.